|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Duenas-Gonzalez A, Serrano-Olvera A,
Cetina L and Coronel J: New molecular targets against cervical
cancer. Int J Womens Health. 6:1023–1031. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
de Freitas AC, Gomes Leitão Mda C and
Coimbra EC: Prospects of molecularly-targeted therapies for
cervical cancer treatment. Curr Drug Targets. 16:77–91. 2015.
View Article : Google Scholar
|
|
4
|
Cummins JM and Velculescu VE: Implications
of micro-RNA profiling for cancer diagnosis. Oncogene.
25:6220–6227. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Miska EA: How microRNAs control cell
division, differentiation and death. Curr Opin Genet Dev.
15:563–568. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Croce CM and Calin GA: miRNAs, cancer, and
stem cell division. Cell. 122:6–7. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kozomara A and Griffiths-Jones S: miRBase:
Annotating high confidence microRNAs using deep sequencing data.
Nucleic Acids Res. 42:D68–D73. 2014. View Article : Google Scholar :
|
|
8
|
He L, Thomson JM, Hemann MT,
Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe
SW, Hannon GJ, et al: A microRNA polycistron as a potential human
oncogene. Nature. 435:828–833. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Munker R and Calin GA: MicroRNA profiling
in cancer. Clin Sci. 121:141–158. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li C, Feng Y, Coukos G and Zhang L:
Therapeutic microRNA strategies in human cancer. AAPS J.
11:747–757. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Huang WC, Chan SH, Jang TH, Chang JW, Ko
YC, Yen TC, Chiang SL, Chiang WF, Shieh TY, Liao CT, et al:
miRNA-491–5p and GIT1 serve as modulators and biomarkers for oral
squamous cell carcinoma invasion and metastasis. Cancer Res.
74:751–764. 2014. View Article : Google Scholar
|
|
12
|
Guo R, Wang Y, Shi WY, Liu B, Hou SQ and
Liu L: MicroRNA miR-491–5p targeting both TP53 and Bcl-XL induces
cell apoptosis in SW1990 pancreatic cancer cells through
mitochondria mediated pathway. Molecules. 17:14733–14747. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Denoyelle C, Lambert B, Meryet-Figuière M,
Vigneron N, Brotin E, Lecerf C, Abeilard E, Giffard F, Louis MH,
Gauduchon P, et al: miR-491–5p-induced apoptosis in ovarian
carcinoma depends on the direct inhibition of both
BCL-XL and EGFR leading to BIM activation. Cell Death
Dis. 5:e14452014. View Article : Google Scholar
|
|
14
|
Li X, Liu Y, Granberg KJ, Wang Q, Moore
LM, Ji P, Gumin J, Sulman EP, Calin GA, Haapasalo H, et al: Two
mature products of MIR-491 coordinate to suppress key cancer
hallmarks in glio-blastoma. Oncogene. 34:1619–1628. 2015.
View Article : Google Scholar
|
|
15
|
Leivonen SK, Sahlberg KK, Mäkelä R, Due
EU, Kallioniemi O, Børresen-Dale AL and Perälä M: High-throughput
screens identify microRNAs essential for HER2 positive breast
cancer cell growth. Mol Oncol. 8:93–104. 2014. View Article : Google Scholar
|
|
16
|
Zhou Y, Li Y, Ye J, Jiang R, Yan H, Yang
X, Liu Q and Zhang J: MicroRNA-491 is involved in metastasis of
hepatocellular carcinoma by inhibitions of matrix metalloproteinase
and epithelial to mesenchymal transition. Liver Int. 33:1271–1280.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nakano H, Miyazawa T, Kinoshita K, Yamada
Y and Yoshida T: Functional screening identifies a microRNA,
miR-491 that induces apoptosis by targeting Bcl-XL in
colorectal cancer cells. Int J Cancer. 127:1072–1080. 2010.
View Article : Google Scholar
|
|
18
|
Yan W, Zhang W, Sun L, Liu Y, You G, Wang
Y, Kang C, You Y and Jiang T: Identification of MMP-9 specific
microRNA expression profile as potential targets of anti-invasion
therapy in glioblastoma multiforme. Brain Res. 1411:108–115.
2011.PubMed/NCBI
|
|
19
|
Rutnam ZJ and Yang BB: The non-coding 3′
uTR of CD44 induces metastasis by regulating extracellular matrix
functions. J Cell Sci. 125:2075–2085. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hacker NF: Revised FIGO staging for
carcinoma of the vulva. Int J Gynaecol Obstet. 105:105–106. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Libra M, Scalisi A, Vella N, Clementi S,
Sorio R, Stivala F, Spandidos DA and Mazzarino C: Uterine cervical
carcinoma: Role of matrix metalloproteinases (Review). Int J Oncol.
34:897–903. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ghosh A, Moirangthem A, Dalui R, Ghosh T,
Bandyopadhyay A, Dasgupta A, Banerjee U, Jana N and Basu A:
Expression of matrix metalloproteinase-2 and 9 in cervical
intraepithelial neoplasia and cervical carcinoma among different
age groups of premenopausal and postmenopausal women. J Cancer Res
Clin Oncol. 140:1585–1593. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shi YA, Zhao Q, Zhang LH, Du W, Wang XY,
He X, Wu S and Li YL: Knockdown of hTERT by siRNA inhibits cervical
cancer cell growth in vitro and in vivo. Int J Oncol. 45:1216–1224.
2014.PubMed/NCBI
|
|
24
|
Ventura A and Jacks T: MicroRNAs and
cancer: Short RNAs go a long way. Cell. 136:586–591. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu JP, Chen W, Schwarer AP and Li H:
Telomerase in cancer immunotherapy. Biochim Biophys Acta.
1805:35–42. 2010. View Article : Google Scholar
|
|
26
|
Chen H, Li Y and Tollefsbol TO: Strategies
targeting telomerase inhibition. Mol Biotechnol. 41:194–199. 2009.
View Article : Google Scholar :
|
|
27
|
Shay JW and Bacchetti S: A survey of
telomerase activity in human cancer. Eur J Cancer. 33:787–791.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gül I, Dündar O, Bodur S, Tunca Y and
Tütüncü L: The status of telomerase enzyme activity in benign and
malignant gynaecologic pathologies. Balkan Med J. 30:287–292.
2013.
|
|
29
|
Rosa MI, Medeiros LR, Bozzetti MC, Fachel
J, Wendland E, Zanini RR, Moraes AB and Rosa DD: Accuracy of
telomerase in cervical lesions: A systematic review. Int J Gynecol
Cancer. 17:1205–1214. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang W and Xing L: RNAi gene therapy of
SiHa cells via targeting human TERT induces growth inhibition and
enhances radiosensitivity. Int J Oncol. 43:1228–1234.
2013.PubMed/NCBI
|
|
31
|
Cifuentes-Rojas C and Shippen DE:
Telomerase regulation. Mutat Res. 730:20–27. 2012. View Article : Google Scholar :
|
|
32
|
Noël JF and Wellinger RJ: Exposing secrets
of telomere-telom-erase encounters. Cell. 150:453–454. 2012.
View Article : Google Scholar
|
|
33
|
Mitomo S, Maesawa C, Ogasawara S, Iwaya T,
Shibazaki M, Yashima-Abo A, Kotani K, Oikawa H, Sakurai E, Izutsu
N, et al: Downregulation of miR-138 is associated with
overexpression of human telomerase reverse transcriptase protein in
human anaplastic thyroid carcinoma cell lines. Cancer Sci.
99:280–286. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang YY, Sun G, Luo H, Wang XF, Lan FM,
Yue X, Fu LS, Pu PY, Kang CS, Liu N, et al: miR-21 modulates hTERT
through a STAT3-dependent manner on glioblastoma cell growth. CNS
Neurosci Ther. 18:722–728. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chen L, Lü MH, Zhang D, Hao NB, Fan YH, Wu
YY, Wang SM, Xie R, Fang DC, Zhang H, et al: miR-1207–5p and
miR-1266 suppress gastric cancer growth and invasion by targeting
telom-erase reverse transcriptase. Cell Death Dis. 5:e10342014.
View Article : Google Scholar
|
|
36
|
Wu J, Chen C and Zhao KN:
Phosphatidylinositol 3-kinase signaling as a therapeutic target for
cervical cancer. Curr Cancer Drug Targets. 13:143–156. 2013.
View Article : Google Scholar : PubMed/NCBI
|
